CN108349997B - 色氨酸双加氧酶（ido1和tdo）抑制剂及其在治疗中的用途 - Google Patents

色氨酸双加氧酶（ido1和tdo）抑制剂及其在治疗中的用途 Download PDF

Info

Publication number
CN108349997B
CN108349997B CN201680063267.2A CN201680063267A CN108349997B CN 108349997 B CN108349997 B CN 108349997B CN 201680063267 A CN201680063267 A CN 201680063267A CN 108349997 B CN108349997 B CN 108349997B
Authority
CN
China
Prior art keywords
group
compound
phenyl
pyridin
dimethylisoxazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680063267.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108349997A (zh
Inventor
B·D·帕尔默
L-M·秦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CN108349997A publication Critical patent/CN108349997A/zh
Application granted granted Critical
Publication of CN108349997B publication Critical patent/CN108349997B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201680063267.2A 2015-08-27 2016-08-25 色氨酸双加氧酶（ido1和tdo）抑制剂及其在治疗中的用途 Active CN108349997B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ711514 2015-08-27
NZ71151415 2015-08-27
PCT/NZ2016/050135 WO2017034420A1 (en) 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Publications (2)

Publication Number Publication Date
CN108349997A CN108349997A (zh) 2018-07-31
CN108349997B true CN108349997B (zh) 2025-06-10

Family

ID=58100623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063267.2A Active CN108349997B (zh) 2015-08-27 2016-08-25 色氨酸双加氧酶（ido1和tdo）抑制剂及其在治疗中的用途

Country Status (9)

Country Link
US (2) US11414428B2 (https=)
EP (1) EP3350188B1 (https=)
JP (2) JP7334041B2 (https=)
KR (1) KR20180048798A (https=)
CN (1) CN108349997B (https=)
AU (2) AU2016312848A1 (https=)
CA (1) CA2996681C (https=)
WO (1) WO2017034420A1 (https=)
ZA (1) ZA201800787B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
WO2018223969A1 (zh) * 2017-06-05 2018-12-13 复旦大学 N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
CN112823036B (zh) * 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
JP2025507981A (ja) 2022-03-04 2025-03-21 アンティド セラピューティクス インターナショナル ソシエテ ア レスポンサビリテ リミティー トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の二重阻害剤と療法におけるそれらの使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813606A1 (en) * 2004-11-18 2007-08-01 Takeda Pharmaceutical Company Limited Amide compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255410A1 (en) 2000-04-14 2001-10-30 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
US20070197610A1 (en) 2004-03-16 2007-08-23 Janssen Pharmaceutica N.V. Benzisoxazoles
DE102005018389A1 (de) 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
BRPI1009428A2 (pt) 2009-03-10 2016-03-01 Gruenenthal Gmbh 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
WO2011100614A1 (en) 2010-02-11 2011-08-18 Vanderbilt University BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
PL2595995T3 (pl) 2010-07-22 2016-05-31 Basf Se Chwastobójcze izoksazolo[5,4-b]pirydyny
JP2015504889A (ja) 2012-01-12 2015-02-16 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草性イソオキサゾロ［５，４−ｂ］ピリジン
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
CN105209449B (zh) 2013-03-14 2019-02-01 库拉德夫制药私人有限公司 犬尿氨酸途径的抑制剂
WO2015082499A2 (en) 2013-12-03 2015-06-11 Iomet Pharma Ltd Pharmaceutical compound
AU2015302908B2 (en) * 2014-08-13 2020-02-13 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
RU2619120C1 (ru) 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813606A1 (en) * 2004-11-18 2007-08-01 Takeda Pharmaceutical Company Limited Amide compound

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure–mutagenicity relationships for arylamine metabolites;Mark S.Tichenor et al.;《Bioorganic & Medicinal Chemistry Letters》;20121022;第22卷(第4期);7357-7362 *
SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF NEW SULFONAMIDE ISOXAZOLO[5,4-b]PYRIDINE DERIVATIVES;KRYSTYNA POREBA ET AL.;《Acta Poloniae Pharmaceutica-Drug Research》;20150731;第72卷(第4期);727-735 *
SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY IN VITRO OF NEW 3-SUBSTITUTED AMINOISOXAZOLO[5,4-b]PYRIDINES;KRYSTYNA POREBA ET AL.;《Acta Poloniae Pharmaceutica-Drug Research》;20031231;第60卷(第4期);293-301 *

Also Published As

Publication number Publication date
CA2996681A1 (en) 2017-03-02
ZA201800787B (en) 2025-08-27
AU2016312848A1 (en) 2018-03-29
AU2021212003B2 (en) 2023-09-14
EP3350188A1 (en) 2018-07-25
JP2018525430A (ja) 2018-09-06
CA2996681C (en) 2024-04-09
WO2017034420A1 (en) 2017-03-02
US20220411438A1 (en) 2022-12-29
KR20180048798A (ko) 2018-05-10
CN108349997A (zh) 2018-07-31
EP3350188A4 (en) 2019-04-03
JP7334041B2 (ja) 2023-08-28
US20180244692A1 (en) 2018-08-30
AU2021212003A1 (en) 2021-08-26
US11414428B2 (en) 2022-08-16
JP2022033753A (ja) 2022-03-02
HK1258665A1 (en) 2019-11-15
EP3350188B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
CN108349997B (zh) 色氨酸双加氧酶（ido1和tdo）抑制剂及其在治疗中的用途
US12508268B2 (en) Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
CN102112447B (zh) 来自吡哆醇的hiv整合酶抑制剂
CN106866571A (zh) 杂环脲类化合物及其药物组合物和应用
CN108530444A (zh) 一种新型nampt和ido双重抑制剂及其制备方法和医药用途
US6197797B1 (en) Cyanoguanidines as cell proliferation inhibitors
HK1039116A1 (zh) 用作細胞增殖抑制劑的氰基胍化合物
CN103664734A (zh) 杂环羟肟酸类化合物及其药用组合物和应用
HK1258665B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549A1 (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
CZ419199A3 (cs) Kyanoguanidiny jako inhibitory buněčné proliferace
CZ9904237A3 (cs) Kyanoguanidiny jako inhibitory buněčné proliferace

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant